

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6506578

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MATTHEW TOCZKO	08/15/2019
JED HUBBS	08/15/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	NEUROCYCLE THERAPEUTICS, INC.
<b>Street Address:</b>	1 BROADWAY, FL. 14
<b>City:</b>	CAMBRIDGE
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02142
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	16950482
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(650)493-8311
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	650-493-9300
<b>Email:</b>	patentdocket@wsgr.com, lfralick@wsgr.com
<b>Correspondent Name:</b>	WILSON SONSINI GOODRICH & ROSATI
<b>Address Line 1:</b>	650 PAGE MILL ROAD
<b>Address Line 4:</b>	PALO ALTO, CALIFORNIA 94304-1050
<b>ATTORNEY DOCKET NUMBER:</b>	54425-703.301
<b>NAME OF SUBMITTER:</b>	DAVID MATA
<b>SIGNATURE:</b>	/David Mata/
<b>DATE SIGNED:</b>	01/21/2021
<b>Total Attachments: 2</b>	
source=54425-703.301 - Executed Assignment#page1.tif	
source=54425-703.301 - Executed Assignment#page2.tif	

## PATENT ASSIGNMENT

Docket Number 54425-703.601

WHEREAS, the undersigned:

- |   |  |
|---|--|
| 1. Matthew TOCZKO<br>1 Broadway, Fl. 14<br>Cambridge, MA 02142 US | 2. Jed HUBBS<br>1 Broadway, Fl. 14<br>Cambridge, MA 02142 US |
|---|--|

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in  
**GABAA POSITIVE ALLOSTERIC MODULATOR COMPOUNDS FOR TREATMENT OF ITCH AND/ OR DERMATITIS**

for which a PCT application serial number PCT/US19/33598 was filed on May 22, 2019 in the U.S. Receiving Office of the Patent Cooperation Treaty;

(hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, NeuroCycle Therapeutics, Inc., a corporation incorporated under the laws of the State of Delaware, having a principal place of business at 1 Broadway, Fl. 14, Cambridge, MA 02142, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.




3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of [wherever the company was formed/registered], without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

PATENT ASSIGNMENT		Docket Number	54425-703.601
Date: <u>15-Aug-17</u>	 Matthew TOCZKO	Date: <u>15-Aug-2019</u>	 Jed HUBBS
RECEIVED AND AGREED TO BY ASSIGNEE: NEUROCYCLE THERAPEUTICS, INC.			
Date: <u>15-Aug-2019</u>	Signature: 	Name: <u>Jed Hubbs</u>	Title: <u>CEO</u>